New Amsterdam sees success in Phase III cardiovascular disease trial
The trial of the combination of obicetrapib and ezetimibe is designed to work for patients whom existing cholesterol therapies aren’t working.
21 November 2024
21 November 2024
The trial of the combination of obicetrapib and ezetimibe is designed to work for patients whom existing cholesterol therapies aren’t working.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.